Can-Fite Reports Namodenoson Liver Cirrhosis Case
RAMAT GAN, Israel — September 9, 2026 Can-Fite BioPharma Ltd. announced publication of a peer-reviewed case report describing clinical...
Namodenoson
Advertisement
Can-Fite Reports Longer Overall Survival in Phase III Liver Cancer Study
RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...
Can-Fite BioPharma Reports Namodenoson Pancreatic Cancer Findings
Ramat Gan, Israel — August 17, 2026 Can-Fite BioPharma Ltd. announced new preclinical findings showing that namodenoson enhanced the...
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
Can-Fite Phase 2a Namodenoson Pancreatic Cancer Data Accepted at ESMO 2026
RAMAT GAN, Israel, July 20, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that positive Phase 2a clinical trial...
Advertisements
Can-Fite Secures Australian Patent for Namodenoson in Liver and Pancreatic Cancer
Ramat Gan, Israel, July 14, 2026 Can-Fite BioPharma announced that the Australian Patent Office has allowed Patent Application No....
Can-Fite Reports Positive Phase 2a Namodenoson Safety Datar
Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...
Morphocell Secures $50M to Advance Stem-Cell Liver Therapy
Laval, Québec, December 1, 2025 — Morphocell Technologies has announced the successful completion of its US$50 million Series A...
Can-Fite Highlights Major Progress Across Late-Stage Drug Pipeline
Ramat Gan, Israel, November 26, 2025 — Can-Fite BioPharma has announced key updates across its advanced-stage clinical pipeline ahead...
Advertisement
